Adjuvant radiotherapy for a prostate cancer after renal transplantation and review of the literature

Japanese Journal of Clinical Oncology

Volumn 41, Issue 11, 2011, Pages 1282-1286

  Detti, Beatrice ^a   Scoccianti, Silvia ^a   Franceschini, Davide ^a   Villari, Donata ^b   Greto, Daniela ^a   Cipressi, Samantha ^a   Sardaro, Angela ^c   Zanassi, Maria ^b   Cai, Tommaso ^d   Biti, Giampaolo ^a  

^a AOU Careggi   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Prostate cancer; Radiotherapy; Renal transplantation

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTATE SPECIFIC ANTIGEN; RAPAMYCIN;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSITY MODULATED RADIATION THERAPY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 80155179733     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr133     Document Type: Article

References (22)

1. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999;68:1859-64.
2. Penn I. Neoplastic Complications of Organ Transplantation. Malden, MA: Blackwell, 1999;770.
3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
4. Kessler M, Jay N, Molle R, Guillemin F Excess risk of cancer in renal transplant patients. Transpl Int 2006;19:908-14.
5. US Renal Data System (USRDS). Annual Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, 2007.
6. Bhandari S, Eris J. Drug points: premature osteonecrosis and sirolimus treatment in renal transplantation. BMJ 2001;323:665.
7. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998;147-58.
8. Sheil AG. Patterns of malignancies following renal transplantation. Transplant Proc 1999;31:1263-5.
9. Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation 2003;75:237-9.
10. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-9.
11. Kleinclauss F, Gigante M, Neuzillet Y, Mouzin M, Terrier N, Salomon L, et al. Prostate cancer in renal transplant recipients. Renal Transplantation Committee of the French Urological Association (AFU). Nephrol Dial Transplant 2008;23:2374-80.
12. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
13. Pollard M. Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A. Cancer Lett 1997;111:221-4.
14. David KM, Morris JA, Steffen BJ, Chi-Burris KS, Gotz VP, Gordon RD. Mycophenolate mofetil versus azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transpl 2005;19:279-85.
15. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5:2954-60.
16. Ekberg H, Grinyo J, Nashan B, Vanrenterghme A, Vincenti F, Voulgari A, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007;7:560-70.
17. Campistol JM, Eris J, Oberbauer R, Friend C, Hutchinson B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9.
18. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BDI. Maintenance immunosuppression with target-of-rapamycin inhibitor is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-9.
19. Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, DeFijter JW, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007;22(Suppl 1):i36-41.
20. Emami B, Lyman J, Brown A, Coia L, Goiten M, Munsenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
21. Konety BR, Tewari A, Howard RJ, Barry JM, Hodge EE, Taylor M, et al. Prostate cancer in the posttransplant population. Urologic Society for Transplantation and Vascular Surgery. Urology 1998;52:428.
22. Mouzin M, Bachaud JM, Kamar N, Gamé X, Vaessen C, Rischmann P, et al. Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation 2004;78:1496-500.